News|Articles|August 24, 2026

National Psoriasis Awareness Month 2026: More Oral Options, Wider Access, and a Systemic Lens

Author(s)Marie Bosslett, Assistant Editor

New trials show oral psoriasis drugs rival biologics, expand care across ages, and spotlight systemic risks—plus the ongoing fight for access. Read our exclusive recap for PsO Action Month.

Psoriasis Awareness Month lands this year amid a wave of trial readouts and clinical commentary that, taken together, point to a field in transition. Oral therapies are closing in on the efficacy once reserved for injectable biologics, treatment is expanding to younger and older patients, and specialists are increasingly framing psoriasis as a systemic disease that extends well beyond the skin.

Related to this article

October 10th, 2026

Liver Function Test Elevations Rare With Biologics in Psoriasis and HS

In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.

October 10th, 2026

Roflumilast Eases Sexual Difficulties in Psoriasis With Genital Involvement

Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.

October 9th, 2026

Ixekizumab Plus Tirzepatide Shifts Biomarkers in Psoriasis with Obesity

By week 36, combination therapy altered 482 proteins and 467 genes vs 140 and 16 with ixekizumab alone in exploratory TOGETHER-PsO data.

October 2nd, 2026

Icotrokinra Sustains Skin Clearance at High-Impact Psoriasis Sites Through 2 Years

At 2 years, 70% of patients on oral icotrokinra for scalp, genital, or hand/foot psoriasis had clear or almost clear skin, with no new safety signals.

$FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults$

October 15th, 2026

FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults

The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.

October 14th, 2026

EADV 2026: DecisionDx-Melanoma Data Support Risk-Based SLNB Decisions in Cutaneous Melanoma

Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.

October 14th, 2026

Q&A: Falk G. Bechara, MD, on Long-Term Tunnel Control and Structural Damage in HS

Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.

October 14th, 2026

Galderma to Acquire ZO Skin Health for $1.5 Billion

Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.